BrainStorm Cell Therapeutics Shares To Resume Trading At 7:10 AM ET; FDA Advisory Committee Voted Wednesday That NurOwn Did Not Demonstrate Substantial Evidence Of Effectiveness For Treatment Of Mild To Moderate ALS
Portfolio Pulse from Charles Gross
The FDA advisory committee voted that NurOwn, a product of BrainStorm Cell Therapeutics, did not demonstrate substantial evidence of effectiveness for the treatment of mild to moderate ALS. Trading of BrainStorm shares is set to resume at 7:10 AM ET.
September 28, 2023 | 10:52 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
BrainStorm Cell Therapeutics' stock may be negatively impacted as the FDA advisory committee did not find substantial evidence of effectiveness for their product, NurOwn, in treating ALS.
The FDA's lack of confidence in NurOwn's effectiveness in treating ALS could lead to a decrease in investor confidence in BrainStorm Cell Therapeutics, potentially leading to a drop in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100